Drug Detail

Information about Recentin

Generic Name	cediranib
IND	AZD2171
Brand Name (US)	Recentin
Manufacturer	AstraZeneca
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 3
Indications
Overall Strategy	GIST Tumor Based KIT Protein Based
Strategy	Block KIT Block tumor blood vessel growth
Drug Category	KIT/PDGFRA inhibitor VEGFR inhibitor (TKI)

This drug is manufactured by AstraZeneca. It is a tyrosine kinase inhibitor of all of the VEGF receptors (VEGFR1, VEGFR2 and VEGFR3), as well as KIT and (less potently) PDGFRA and PDGFRB.

The phase II clinical trial evaluated the biological activity of AZD2171 as Measured by FDG-PET Response, in Patients With Metastatic GIST resistant or intolerant to imatinib (Gleevec). Trial sites were in London, United Kingdom (recruiting) and Manchester, United Kingdom.